Results of the IDEAL LM trial showed patients with left main coronary artery disease treated with Boston Scientific Corp.'s Synergy everolimus-eluting platinum-chromium stent with a biodegradable polymer fared equally well with short-duration dual antiplatelet therapy (DAPT) as patients treated with Abbott Laboratories Inc.'s Xience everolimus-eluting cobalt-chromium stent and a standard 12-month course of antiplatelet therapy.
Robert-Jan Van Geuns, from Erasmus Medical Center in Rotterdam, reported the results on 26 September at Transcatheter Cardiovascular Therapeutics meeting...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?